Cingulate (CING) Expected to Announce Earnings on Tuesday

Key Points

• Cingulate is expected to report Q2 2026 results before the market opens on August 18. Analysts forecast a loss of $0.63 per share and revenue of approximately $167,000; the company’s earnings call is scheduled for August 20.
• The company previously reported a quarterly loss of $0.95 per share, missing consensus expectations by $0.42. Analysts project full-year and next-year losses of approximately $2 and $1 per share, respectively.
• Cingulate shares opened at $5.25, with a market capitalization of about $70.7 million, while institutional investors own 41.3% of the stock. Despite mixed ratings, the analyst consensus is “Moderate Buy” with a $27.33 target price.

Cingulate (NASDAQ:CING - Get Free Report) is expected to post its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Cingulate to announce earnings of ($0.63) per share and revenue of $0.1670 million for the quarter. Parties are encouraged to explore the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 9:30 AM ET.

Cingulate (NASDAQ:CING - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.42). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cingulate Stock Down 1.7%

CING opened at $5.25 on Tuesday. Cingulate has a twelve month low of $3.16 and a twelve month high of $11.89. The company has a fifty day moving average of $4.88 and a 200-day moving average of $5.60. The stock has a market cap of $70.72 million, a PE ratio of -1.24 and a beta of -0.90.

Institutional Trading of Cingulate

Large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company's stock worth $31,000 after buying an additional 5,543 shares during the period. XTX Topco Ltd bought a new position in Cingulate in the second quarter worth approximately $45,000. Quadrature Capital Ltd acquired a new stake in Cingulate in the fourth quarter valued at approximately $66,000. Geode Capital Management LLC grew its stake in Cingulate by 43.9% in the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock valued at $265,000 after acquiring an additional 18,629 shares during the period. Finally, Kestra Advisory Services LLC increased its holdings in shares of Cingulate by 29.8% during the fourth quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company's stock valued at $529,000 after acquiring an additional 27,979 shares in the last quarter. 41.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings raised shares of Cingulate from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, July 24th. Ascendiant Capital Markets lowered their price objective on Cingulate from $55.00 to $52.00 and set a "buy" rating for the company in a research report on Monday, June 8th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Cingulate in a research note on Tuesday, May 26th. Wall Street Zen lowered Cingulate from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 16th. Finally, Roth Capital restated a "buy" rating and set a $10.00 target price on shares of Cingulate in a research report on Tuesday, May 19th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $27.33.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source